公开(公告)号：US06835832B2

公开(公告)日：2004-12-28

申请号：US10361731

申请日：2003-02-10

申请人： Lin-Hua Zhang ,  Lei Zhu

发明人： Lin-Hua Zhang ,  Lei Zhu

IPC分类号： C07D295135

CPC分类号： C07D401/12 ,  C07D231/40 ,  C07D401/14 ,  C07D405/12

摘要： Disclosed are novel processes and novel intermediate compounds for preparing aryl-and heteroaryl-substituted urea compounds of the formula(I) wherein Ar1, Ar2, L, Q and X are described herein. The product compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases.

摘要翻译： 公开了用于制备式（I）的芳基和杂芳基取代的脲化合物的新方法和新型中间体化合物，其中本文描述了Ar1，Ar2，L，Q和X。 产品化合物可用于治疗涉及炎症的疾病或病理状况的药物组合物，例如慢性炎性疾病。

公开(公告)号：US06548498B1

公开(公告)日：2003-04-15

申请号：US09171575

申请日：1998-10-21

申请人： Stefan Berg ,  Lennart Florvall ,  Svante Ross ,  Seth-Olov Thorberg

发明人： Stefan Berg ,  Lennart Florvall ,  Svante Ross ,  Seth-Olov Thorberg

IPC分类号： C07D295135

CPC分类号： C07D295/135 ,  C07D295/155

摘要： The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives of the formula I as (R)-enantiomers, (S)-enantiomers, or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof. The present invention further relates to a process for the preparation of the compounds, to pharmaceutical compositions containing the compounds and to methods of treatment of 5-hydroxytryptamine-mediated disorders comprising administering the compounds.

摘要翻译： 本发明涉及式Ias（R） - 对映异构体，（S） - 对映异构体或游离碱形式的外消旋物或其药学上可接受的盐或溶剂化物的新的哌啶基或哌嗪基取代的茚满衍生物。 本发明还涉及制备所述化合物的方法，含有所述化合物的药物组合物和治疗5-羟色胺介导的病症的方法，包括给予所述化合物。

公开(公告)号：US06410532B1

公开(公告)日：2002-06-25

申请号：US09902000

申请日：2001-07-10

申请人： Stefan Berg ,  Mats Linderberg ,  Svante Ross ,  Seth-Olov Thorberg ,  Bengt Ulff

发明人： Stefan Berg ,  Mats Linderberg ,  Svante Ross ,  Seth-Olov Thorberg ,  Bengt Ulff

IPC分类号： C07D295135

摘要： The present invention relates to new piperidyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having the formula I wherein X is N or CH; Y is NR2CH2, CH2—NR2, NR2—CO, CO—NR2 or NR2SO2 wherein R2 is H or C1-6 alkyl; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted n is 0-4; R9 is C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CN, CF3, OH, C1-C6 alkoxy, C1-C6 alkoxy—C1-C6 alkyl, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein R6, R7 and R8 are as defined above, as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.